What is the clinical efficacy of mabelantuzumab?

Berantuzumab is an innovative antibody-drug conjugate (ADC) for relapsed or refractory multiple myeloma. It is designed for adult patients who have experienced at least four treatments (including anti-CD38 monoclonal antibodies, proteasome inhibitors and immunomodulators) but have failed to effectively control their disease. This drug has demonstrated significant clinical efficacy in the treatment of myeloma through its unique mechanism of action.

Berantuzumab specifically targets and binds to the B cell mature antigens on the surface of multiple myeloma cells. Once bound to the myeloma cells, its antibody component triggers the patient's own immune mechanism and triggers a series of precise immune responses to accurately locate and destroy cancerous myeloma cells. This precision treatment strategy effectively enhances anti-tumor efficacy while minimizing potential damage to healthy cells.

The clinical efficacy of belantuzumab has been verified by multiple clinical trials, the most important of which is thepivotal DREAMM-2 study. The study enrolled patients with relapsed or refractory multiple myeloma who had experienced severe disease progression despite current standard of care. Study results showed that treatment with single-agent belantuzumab 2.5 mg/kg every 3 weeks demonstrated a clinically meaningful overall response rate of 31% in patients who had received a median of seven prior lines of therapy. At the 6-month analysis, the median duration of response (DoR) had not yet been reached, but 73% of responders had a response duration of 6 months or greater, which fully demonstrates the potential of belantuzumab to extend patient survival and improve quality of life.

It is worth noting that although berantuzumab has shown good efficacy in clinical trials, its use still needs to be cautious. During treatment, patients should be reviewed and monitored regularly to detect and manage any potential side effects and complications. At the same time, medical staff should also make personalized adjustments to the dosage according to the patient's specific situation to ensure the safety and effectiveness of the treatment.

In summary, berantuzumab, as an innovative treatment, provides new hope and options for patients with relapsed or refractory multiple myeloma. Its unique mechanism of action and significant clinical efficacy make this drug occupy an important position in the treatment of myeloma.

Reference materials:https://www.drugs.com/search.php?searchterm=Blenrep&sources%5B%5D=professional